These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27657985)

  • 41. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
    Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
    Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overexpression of P53 protein and local hGH, IGF-I, IGFBP-3, IGFBP-2 and PRL secretion by human breast cancer explants.
    Milewicz T; Ryś J; Wójtowicz A; Stochmal E; Jach R; Krzysiek J; Gregoraszczuk E; Huras H; Dziadek O
    Neuro Endocrinol Lett; 2011; 32(3):328-33. PubMed ID: 21670726
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of insulin-like growth factor-1 and insulinlike growth factor binding protein-3 in diagnosis of growth hormone deficiency in short-stature children.
    Ali A; Hashim R; Khan FA; Sattar A; Ijaz A; Manzoor SM; Younas M
    J Ayub Med Coll Abbottabad; 2009; 21(3):40-5. PubMed ID: 20929010
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effects of amino acid solution and recombinant human growth hormone on growth hormone/insulin like growth factor-1 axis in rats with liver cirrhosis].
    Liang LJ; Luo SM; Hu WJ
    Zhonghua Wai Ke Za Zhi; 2005 Jun; 43(11):697-701. PubMed ID: 16008955
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Age- and growth hormone-induced alterations in renal sulfate transport.
    Sagawa K; Han B; DuBois DC; Murer H; Almon RR; Morris ME
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1182-7. PubMed ID: 10454493
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment.
    Kriström B; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2889-98. PubMed ID: 9284715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Measurement of IGF-1, IGFBP-3 and free IGF-1 levels by ELISA in growth hormone (GH) deficient children before and after GH replacement.
    Wacharasindhu S; Aroonparkmongkol S; Srivuthana S
    Asian Pac J Allergy Immunol; 2002 Sep; 20(3):155-60. PubMed ID: 12587838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Values in selected population of athletes.
    Abellan R; Ventura R; Palmi I; di Carlo S; Bacosi A; Bellver M; Olive R; Pascual JA; Pacifici R; Segura J; Zuccaro P; Pichini S
    J Pharm Biomed Anal; 2008 Nov; 48(3):844-52. PubMed ID: 18617352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Leptin, VEGF, IGF-1, and IGFBP-3 concentrations in serum and follicular fluid of women undergoing in vitro fertilization.
    Dorn C; Reinsberg J; Kupka M; van der Ven H; Schild RL
    Arch Gynecol Obstet; 2003 Aug; 268(3):187-93. PubMed ID: 12942249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group.
    Dall R; Longobardi S; Ehrnborg C; Keay N; Rosén T; Jørgensen JO; Cuneo RC; Boroujerdi MA; Cittadini A; Napoli R; Christiansen JS; Bengtsson BA; Sacca L; Baxter RC; Basset EE; Sönksen PH
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4193-200. PubMed ID: 11095453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects.
    Singh I; Patel A; Patel R; Jose V
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):329-337. PubMed ID: 29948023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys.
    Sun YN; Lee HJ; Almon RR; Jusko WJ
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1523-32. PubMed ID: 10336548
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of lycopene supplementation on insulin-like growth factor-1 and insulin-like growth factor binding protein-3: a double-blind, placebo-controlled trial.
    Graydon R; Gilchrist SE; Young IS; Obermüller-Jevic U; Hasselwander O; Woodside JV
    Eur J Clin Nutr; 2007 Oct; 61(10):1196-200. PubMed ID: 17299493
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reproducibility in patterns of IGF generation with special reference to idiopathic short stature.
    Selva KA; Buckway CK; Sexton G; Pratt KL; Tjoeng E; Guevara-Aguirre J; Rosenfeld RG
    Horm Res; 2003; 60(5):237-46. PubMed ID: 14614229
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A low starting dose of genotropin in growth hormone-deficient adults.
    Janssen YJ; Frölich M; Roelfsema F
    J Clin Endocrinol Metab; 1997 Jan; 82(1):129-35. PubMed ID: 8989246
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study.
    Böger RH; Skamira C; Bode-Böger SM; Brabant G; von zur Muhlen A; Frolich JC
    J Clin Invest; 1996 Dec; 98(12):2706-13. PubMed ID: 8981915
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
    Rasmussen MH; Olsen MW; Alifrangis L; Klim S; Suntum M
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1819-29. PubMed ID: 25013997
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport.
    Wallace JD; Cuneo RC; Baxter R; Orskov H; Keay N; Pentecost C; Dall R; Rosén T; Jørgensen JO; Cittadini A; Longobardi S; Sacca L; Christiansen JS; Bengtsson BA; Sönksen PH
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3591-601. PubMed ID: 10523001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects.
    Lee H; Chung H; Lee S; Lee H; Yang SM; Yoon SH; Cho JY; Jang IJ; Yu KS
    BioDrugs; 2017 Aug; 31(4):349-355. PubMed ID: 28551775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.